Letter to Editor: Response to AASLD Editorial/Message from the President.
Hepatology
; 69(5): 2300, 2019 05.
Article
em En
| MEDLINE
| ID: mdl-30276829
ABSTRACT
A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Hepatite C Crônica
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Hepatology
Ano de publicação:
2019
Tipo de documento:
Article